CRISPR Therapeutics Vertex Pharmaceuticals: Better Buy in 2026
Investors face a choice between a high-growth gene-editing bet and a cash-generating biotech leader. This article bre...
Knowing when to switch from passive to active strategies can boost returns. This guide outlines practical signals, costs, and risk considerations.
27,240 articlesInvestors face a choice between a high-growth gene-editing bet and a cash-generating biotech leader. This article bre...
Ripple wins preliminary approval to operate under MiCA in Luxembourg, but the path to a full MiCA license is far from...
Ripple's XRP Ledger is moving toward an on-chain lending layer. This article explains how the ledger's 'missing layer...
New federal data show the median retirement balance for Americans aged 55-64 sits at $185,000, enough for roughly 2.5...
Rising tensions with Iran push jet fuel costs higher, forcing freight operators to hedge, reroute, and stockpile. Thi...
Wells Fargo offers a cheaper entry and higher yield than Bank of America, delivering more bang your buck for income-f...
Grayscale Investments disclosed on July 2, 2026 that its CFO for the Ethereum Staking Mini ETF is leaving after seven...
Toyota strengthens its global cash-flow engine with hybrids and expanding markets, while Ford grapples with EV losses...
Verisign sits at the backbone of the web. It runs the registry for .COM and .NET and powers how users reach sites eve...
Microsoft's Xbox unit is cutting 3,200 jobs as part of a sweeping overhaul aimed at refocusing on the console and cor...
Gemini unveils 0% commission stock trading for eligible U.S. customers, signaling a broader push to become a comprehe...
Markets swing after headlines suggest a faltering Iran ceasefire, reigniting energy risk and shifting bets on Fed pol...